Human papillomavirus (HPV)-associated head and neck cancers, specifically head and neck squamous cell carcinoma (HNSCC), are on the rise worldwide. Yet, the factors contributing to these tumours and their varying responses to treatment remain poorly understood.
List view / Grid view
Bare minimum reimbursement rates could be why some clinics may be struggling to offer HPV vaccination in the US.
A new study modelled chlamydia and HPV co-infection in patient-derived ectocervix organoids to reveal distinct cellular reprogramming.
The discovery of a link between the human leukocyte antigen (HLA) and genital warts may lead to mRNA-based vaccines against HPV and other diseases.
A new study sequenced tumour DNA for the “ultrasensitive” detection of HPV, further honing precision treatment of the illness.
Novel organoid models of cervical cancer and a healthy human cervix have been developed to study the condition and its progression.
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
A study that teases apart the biological mechanisms by which HPV cause cancer, has found a strategy that may provide targeted treatment...
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The grant for the second year of a multi-year R+D project and will be used for Hookipa’s arenaviral vector technologies, cancer immunotherapies and to...